Clinical trials: Fat; Liver
Steatohepatitis, Nonalcoholic
The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis
The aim of the current study is to evaluate the safety and efficay of Montelukast in treatment of patients with fatty liver disease.
- Trial name
- NCT04080947
- Testing
- Control group, Montelukast group
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Sadat City University
NAFLD, Diabetes Mellitus, Type 2
Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Conditions
- NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
- Trial name
- NCT03371355
- Testing
- ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
- Where
- 42 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Akcea Therapeutics
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)
This study is to evaluate the predictive value of NRL972 pharmacokinetics in the diagnosis of steatohepatitis using fatty liver disease as the comparator group.
- Trial name
- NCT00794716
- Testing
- NRL972
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Norgine
HCV Coinfection, HIV Infection
Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection
Primary Objective: To compare the impact of switching from efavirenz (EFV) plus two nucleoside analogs to rategravir (RAL) plus two nucleoside analogs versus keeping the same antiretroviral regimen on hepatic steatosis (HS) as…
- Trial name
- STERAL (NCT01900015)
- Testing
- Raltegravir, Efavirenz
- Where
- 10 sites in Spain
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Juan Macías
Fatty Liver
Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
Background: Non-alcoholic fatty liver disease (NAFLD) is an excess accumulation of fat in the liver cells. It is associated with obesity, high blood pressure, high cholesterol, and diabetes.
- Trial name
- NCT01792115
- Testing
- Vitamin E 200 IU/d, Vitamin E 400 IU/d, Vitamin E 800 IU/d
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infections, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)
Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)
This study aims to identify the risk factors that lead to the development of metabolic liver disease in people who have been newly diagnosed with HIV.
- Conditions
- HIV Infections, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH), Fatty Liver
- Trial name
- MASHIV-TR (NCT07737340)
- Testing
- FibroScan (Transient Elastography), Hepatobiliary Ultrasonography (USG), Clinical and Laboratory Monitoring
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- Yaşar Bayındır, MD
Hepatitis C, Hepatitis B
Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
Liver fibrosis is an important public health problem, with a substantial morbidity and mortality due to progression to cirrhosis and hepatocellular carcinoma. All causes of chronic liver disease may lead to fibrosis.
- Conditions
- Hepatitis C, Hepatitis B, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
- Trial name
- ELF (NCT02044523)
- Testing
- Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Liver Steatosis
Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis
Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition.
- Trial name
- TRANSTEATOSE (NCT02575625)
- Testing
- Fibroscan, Blood test for biological assessment of liver function, MRI
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Non-Alcoholic Fatty Liver Disease
Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases
In developed counties Non-alcoholic fatty liver disease (NAFLD) becomes the most common cause of chronic liver disease , but its prevalence in developing countries like India is also increasing (10 -20%).Till date, there is no…
- Trial name
- NCT04475276
- Testing
- Alphalipoic acid
- Where
- India
- Volunteers
- 120 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Liver Diseases, Humans
Liver Disease and Other Systemic Diseases
Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing…
- Conditions
- Liver Diseases, Humans, Progression, Carcinogenesis
- Trial name
- NCT04525833
- Where
- Taiwan
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Non-alcoholic Fatty Liver Disease, Obesity
Effect of Exercise on Hepatic Fat in Overweight Children
The objective of the present study is to evaluate the effect of 6 months exercise intervention program on hepatic fat fraction in overweight children.
- Conditions
- Non-alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- EFIGRO (NCT02258126)
- Testing
- Multidisciplinary intervention program
- Where
- Spain
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of the Basque Country (UPV/EHU)
Nonalcoholic Fatty Liver Disease, Liver Steatosis
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis
Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China.
- Conditions
- Nonalcoholic Fatty Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT03386890
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Non-alcoholic Fatty Liver Disease
A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men
This study looks at how a new study medicine called NNC0194-0499 behaves in the body of Chinese men. Three different dose levels will be tested. Participant will get only one of the three different dose levels of NNC0194-0499.
- Trial name
- NCT05742919
- Testing
- NNC0194-0499, NC0194-0499
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Plant Stanols and Liver Inflammation in Overweight and Obese Children
Obesity is associated with a variety of co-morbidities. Children with obesity are more likely to have risk factors associated with cardiovascular diseases (CVD) and CVD risk markers (e.g.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, NAFLD, NASH
- Trial name
- NCT04783116
- Testing
- Plant stanols (3g/day)
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- Maastricht University Medical Center
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of the metabolic syndrome. NAFLD is a pathologic condition which involves both hepatic steatosis and non alcoholic steatohepatitis (NASH), as…
- Trial name
- NCT01894438
- Testing
- Mediterranean lifestyle, Mediterranean Diet
- Where
- Greece
- Volunteers
- 63 people
- Sponsor
- Harokopio University
Solid Tumor (Excluding CNS), Liver Cell Carcinoma
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety…
- Conditions
- Solid Tumor (Excluding CNS), Liver Cell Carcinoma, Malignant Rhabdoid Tumor, Yolk Sac Tumor
- Trial name
- IMPACT (NCT07148050)
- Testing
- SC-CAR.GPC3xIL15.21 CAR T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Seattle Children's Hospital
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
This is a randomized, double-blind, placebo-controlled study in up to 104 patients with a diagnosis of Non-alcoholic fatty Liver disease (NAFLD) and/or Non-alcoholic steatohepatitis (NASH).
- Trial name
- EVIDENCES IV (NCT03061721)
- Testing
- Saroglitazar magnesium 1 mg, Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg
- Where
- 18 sites in United States
- Volunteers
- 106 people
- Sponsor
- Zydus Therapeutics Inc.
Fatty Liver
Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter
Background: Non-alcoholic fatty liver disease (NAFLD) affects 30% of the Asian adult population and is emerging as one of the important leading causes of liver cancer and cirrhosis.
- Trial name
- NCT06203548
- Testing
- Lifestyle modification programme
- Where
- Hong Kong
- Volunteers
- 150 people
- Sponsor
- Chinese University of Hong Kong
Non-alcoholic Steatohepatitis
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
This is a Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants.
- Trial name
- NCT05848440
- Testing
- AZD9550
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV Infections
2000 HIV Human Functional Genomics Partnership Program
Background Chronic HIV infection leads to a dysregulated immune system, even when full viral suppression is achieved. HIV causes persistent immune activation, relating to an array of common non-AIDS-related diseases such as…
- Trial name
- 2000HIV (NCT03994835)
- Where
- 4 sites in Netherlands
- Volunteers
- 1,910 people
- Sponsor
- Radboud University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.